EDAP TMS S.A. logo
EDAP TMS S.A. EDAP
report update icon

Quarterly report 2026-Q1
added 05-07-2026

EDAP TMS S.A. Income Statement 2025-2008 | EDAP

Brief overview of profit and loss at EDAP TMS S.A.

The comparison covers a five-year financial horizon. Revenue at EDAP TMS S.A. moved from 44.9 million euros in 2019 to 64.1 million euros in 2024. The cumulative result was +42.8%, corresponding to roughly 7.4% per year. Revenue advanced gradually over the five-year period.

Gross profit changed from 21 million euros to 26.6 million euros (+26.4%). Costs absorbed a larger share of revenue over the period. At the margin level, the figure shifted from 46.8% to 41.4%. A lower margin indicates deterioration in the economics of the core business.

Over the period, EBITDA shifted from 4.1 million euros to −18 million euros, a change of −540.4%. EBITDA lagged revenue, showing weaker operating momentum. EBITDA margin moved from 9.1% to −28%. Cost pressure reduced operating profitability.

The final result was 1.5 million euros initially and −19 million euros in the final year. The emergence of a loss requires close attention to costs and the operating model.

Market value was 110 million euros at the start and 60 million euros at the end. Financial performance is stronger than the share-price trend.

Financial takeaway

Signs of deterioration dominate the five-year picture. The strongest signals are sales growth. The most visible risks are a narrow EBITDA buffer, a declining EBITDA margin and a weaker market valuation. Future reports should be judged by revenue momentum, margins, and the conversion of sales into net income.

Annual Income Statement EDAP TMS S.A.

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

Market Cap

139 M 60 M 280 M 265 M 225 M 225 M 110 M 77.1 M 74.4 M 90.4 M 88.6 M 71.7 M 63.2 M 46.7 M 33.1 M 33.8 M 16.2 M -

Shares

37.4 M 37.3 M 37 M 34.4 M 32.1 M 29.1 M 29 M 29 M 29 M 27.8 M 25 M 23.6 M 20.6 M 17.6 M 13.3 M 13 M 10.5 M -

Historical Prices

3.71 1.61 7.57 7.7 7 7.71 3.8 2.66 2.57 3.21 3.54 3.04 3.12 2.58 2.5 2.6 1.54 3.55

Net Income

- -19 M -21.2 M -2.93 M 700 K -1.7 M 1.51 M -338 K -681 K 3.84 M -1.67 M -512 K -5.02 M -7.48 M -938 K -12.7 M -7.77 M -

Revenue

- 64.1 M 60.4 M 55.1 M 44.1 M 47.8 M 44.9 M 39.2 M 35.7 M 35.6 M 32.3 M 26.8 M 24.1 M 26.1 M 22.3 M 23.7 M 24.9 M -

Cost of Revenue

- 37.6 M 36 M 30.9 M 25.6 M 23.3 M 23.9 M 22.3 M 20.9 M 19.2 M 18.5 M 15.6 M 14.8 M 15.6 M 13.4 M 14.3 M 14.2 M -

Gross Profit

- 26.6 M 24.4 M 24.2 M 18.4 M 18.4 M 21 M 16.9 M 14.8 M 16.4 M 13.8 M 11.2 M 9.32 M 10.4 M 8.86 M 9.46 M 10.7 M -

Operating Income

- -20.5 M -19.8 M -4.26 M -1.61 M 269 K 2.2 M -1.32 M -2.03 M 392 K 488 K -1.74 M -2.76 M -2.03 M -2.5 M -3.82 M -3.2 M -

Interest Expense

- - 232 K 168 K 52 K 108 K 165 K 111 K 44 K 57 K 64 K -65 K -1.97 M -2.06 M -875 K -2.14 M - -

EBITDA

- -18 M -17.9 M -2.65 M 308 K 2.37 M 4.08 M 295 K -454 K 1.42 M 1.49 M -837 K -1.58 M -1.1 M -1.08 M -2.58 M -1.4 M -

Operating Expenses

- 47.1 M 44.2 M 28.4 M - 20.8 M 18.8 M 18.2 M 16.8 M 16 M 13.3 M 12.9 M 36 M 36 M 35 M -13.3 M - -

General and Administrative Expenses

- 14.1 M 14.6 M 7.15 M 5.9 M - 4.22 M 3.59 M 3.43 M 3.3 M 3.2 M 3.33 M 3.2 M 3.18 M 3.04 M 3.32 M 3.82 M -

All numbers in EUR currency

Quarterly Income Statement EDAP TMS S.A.

2026-Q1 2025-Q4 2024-Q4 2023-Q4 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1 2010-Q4 2009-Q4 2008-Q4

Shares

37.5 M - - - - - - - 33.5 M - - - 29.2 M - - - 29.1 M - - - 29 M - 29 M - 29 M - 29 M - 28.7 M - 28.7 M - 25.4 M - 25 M - 24.9 M - 24.8 M - 21.8 M - - - - - - - - - - - 13 M 10.5 M -

Net Income

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -12.7 M -7.77 M -

Revenue

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 23.7 M 24.9 M -

Cost of Revenue

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 14.3 M 14.2 M -

Gross Profit

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 9.46 M 10.7 M -

Operating Income

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -3.82 M -3.2 M -

Interest Expense

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -2.14 M - -

EBITDA

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -2.58 M -1.4 M -

Operating Expenses

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -13.3 M - -

General and Administrative Expenses

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 3.32 M 3.82 M -

All numbers in EUR currency

The income statement is one of the three key financial reports of a company EDAP TMS S.A. (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
Second Sight Medical Products Second Sight Medical Products
EYES
- -0.97 % $ 54.4 M usaUSA
GenMark Diagnostics, Inc. GenMark Diagnostics, Inc.
GNMK
- - $ 1.77 B usaUSA
Lianluo Smart Limited Lianluo Smart Limited
LLIT
- 24.59 % $ 44.8 M chinaChina
Obalon Therapeutics, Inc. Obalon Therapeutics, Inc.
OBLN
- -5.86 % $ 30.6 M usaUSA
Aziyo Biologics Aziyo Biologics
AZYO
- 1.37 % $ 20.5 M usaUSA
AxoGen AxoGen
AXGN
$ 48.73 1.42 % $ 2.24 B usaUSA
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
BioSig Technologies BioSig Technologies
BSGM
- 37.08 % $ 85.7 M usaUSA
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
CHF Solutions, Inc. CHF Solutions, Inc.
CHFS
- 1.15 % $ 34.5 M usaUSA
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
Integra LifeSciences Holdings Corporation Integra LifeSciences Holdings Corporation
IART
$ 18.34 0.55 % $ 1.41 B usaUSA
BIOLASE BIOLASE
BIOL
- -13.19 % $ 166 K usaUSA
Soliton, Inc. Soliton, Inc.
SOLY
- -1.42 % $ 435 M usaUSA
Hancock Jaffe Laboratories, Inc. Hancock Jaffe Laboratories, Inc.
HJLI
- -1.98 % $ 98.3 M usaUSA
Itamar Medical Ltd. Itamar Medical Ltd.
ITMR
- 0.03 % $ 1.58 B israelIsrael
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
IRIDEX Corporation IRIDEX Corporation
IRIX
$ 0.86 3.87 % $ 14.6 M usaUSA
Misonix, Inc. Misonix, Inc.
MSON
- - $ 462 M usaUSA
Dynatronics Corporation Dynatronics Corporation
DYNT
- 14.99 % $ 929 K usaUSA
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
Cutera Cutera
CUTR
- -10.19 % $ 1.99 M usaUSA
Eargo Eargo
EAR
- - $ 10.2 M usaUSA
Intersect ENT, Inc. Intersect ENT, Inc.
XENT
- - $ 955 M usaUSA
GBS GBS
GBS
- -0.57 % $ 7.12 M usaUSA
LivaNova PLC LivaNova PLC
LIVN
$ 82.22 0.02 % $ 4.48 B britainBritain
LENSAR LENSAR
LNSR
$ 8.2 0.24 % $ 98.1 M usaUSA
Avanos Medical Avanos Medical
AVNS
$ 24.99 - $ 1.16 B usaUSA
Invacare Corporation Invacare Corporation
IVC
- - $ 24.7 M usaUSA
MiMedx Group MiMedx Group
MDXG
$ 4.27 1.67 % $ 631 M usaUSA
ClearPoint Neuro ClearPoint Neuro
CLPT
$ 15.34 0.1 % $ 434 M usaUSA
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
Cytosorbents Corporation Cytosorbents Corporation
CTSO
$ 0.4 10.38 % $ 24.9 M usaUSA
SmileDirectClub SmileDirectClub
SDC
- -53.45 % $ 9.71 M usaUSA
Sientra Sientra
SIEN
- -16.59 % $ 10.3 M usaUSA
Silk Road Medical, Inc Silk Road Medical, Inc
SILK
- - $ 1.07 B usaUSA
NanoVibronix NanoVibronix
NAOV
- - $ 1.08 M usaUSA
Surgalign Holdings Surgalign Holdings
SRGA
- -32.98 % $ 1.68 M usaUSA
ShockWave Medical ShockWave Medical
SWAV
- - $ 12.3 B usaUSA
Inogen Inogen
INGN
$ 5.75 0.17 % $ 153 M usaUSA
NuVasive NuVasive
NUVA
- - $ 2.07 B usaUSA
Natus Medical Incorporated Natus Medical Incorporated
NTUS
- 1.94 % $ 1.05 B usaUSA
Nevro Corp. Nevro Corp.
NVRO
- - $ 217 M usaUSA
ThermoGenesis Holdings ThermoGenesis Holdings
THMO
- -25.84 % $ 171 K usaUSA
Talis Biomedical Corporation Talis Biomedical Corporation
TLIS
- 3.55 % $ 7.96 M usaUSA
Titan Medical Titan Medical
TMDI
- -26.32 % $ 19.6 M canadaCanada
Butterfly Network Butterfly Network
BFLY
$ 8.84 0.79 % $ 2.18 B usaUSA
Vapotherm Vapotherm
VAPO
- 6.72 % $ 34 M usaUSA